Evotec SE logo

EVT - Evotec SE Share Price

€23.2 0.2  0.8%

Last Trade - 4:35pm

Large Cap
Market Cap £3.14bn
Enterprise Value £3.27bn
Revenue £417.3m
Position in Universe 210th / 1040
Unlock EVT Revenue
Relative Strength (%)
1m -5.17%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
89.5 127.7 164.5 263.8 375.4 446.4 464.6 528 +37.9%
+334.5 -29.8 +208.4 -41.3 -19.1 +33.9
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Evotec SE revenues increased 15% to EUR119.4M. Net income increased 31% to EUR17.1M. Revenues reflect EVT Execute segment increase of 13% to EUR91.9M, EVT Innovate segment increase of 24% to EUR23.3M, Transition segment increase of 20% to EUR4.1M. Net income benefited from EVT Execute segment income increase of 5% to EUR22.9M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


EVT Revenue Unlock EVT Revenue

Net Income

EVT Net Income Unlock EVT Revenue

Normalised EPS

EVT Normalised EPS Unlock EVT Revenue

PE Ratio Range

EVT PE Ratio Range Unlock EVT Revenue

Dividend Yield Range

EVT Dividend Yield Range Unlock EVT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
EVT EPS Forecasts Unlock EVT Revenue
Profile Summary

Evotec SE is a Germany-based drug discovery alliance and development partnership company. The Company focuses mainly on product approaches with a number of pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated April 1, 2019
Public Since October 11, 1999
No. of Shareholders: n/a
No. of Employees: 3,030
Sector Healthcare
Industry Biotechnology & Medical Research
Index Xetra Prime All Share ,
Exchange XETRA
Shares in Issue 151,226,278
Free Float (0.0%)
Eligible for
EVT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for EVT
Upcoming Events for EVT
Wednesday 12th August, 2020
Q2 2020 Evotec SE Earnings Release
Wednesday 12th August, 2020
Q2 2020 Evotec SE Earnings Call
Thursday 12th November, 2020
Q3 2020 Evotec SE Earnings Release
Frequently Asked Questions for Evotec SE
What is the Evotec SE share price?

As of 4:35pm, shares in Evotec SE are trading at €23.2, giving the company a market capitalisation of £3.14bn. This share price information is delayed by 15 minutes.

How has the Evotec SE share price performed this year?

Shares in Evotec SE are currently trading at €23.2 and the price has moved by -5.73% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Evotec SE price has moved by -1.92% over the past year.

What are the analyst and broker recommendations for Evotec SE?

Of the analysts with advisory recommendations for Evotec SE, there are there are currently 1 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Evotec SE is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Evotec SE next release its financial results?

Evotec SE is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Evotec SE dividend yield?

Evotec SE does not currently pay a dividend.

Does Evotec SE pay a dividend?

Evotec SE does not currently pay a dividend.

When does Evotec SE next pay dividends?

Evotec SE does not currently pay a dividend.

How do I buy Evotec SE shares?

To buy shares in Evotec SE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Evotec SE?

Shares in Evotec SE are currently trading at €23.2, giving the company a market capitalisation of £3.14bn.

Where are Evotec SE shares listed? Where are Evotec SE shares listed?

Here are the trading details for Evotec SE:

Country of listing: Germany
Exchange: GER
Ticker Symbol: EVT
What kind of share is Evotec SE?

Based on an overall assessment of its quality, value and momentum, Evotec SE is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Evotec SE share price forecast 2020?

Shares in Evotec SE are currently priced at €23.2. At that level they are trading at 24.41% discount to the analyst consensus target price of 0.00.

Analysts covering Evotec SE currently have a consensus Earnings Per Share (EPS) forecast of 0.248 for the next financial year.

How can I tell whether the Evotec SE share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evotec SE. Over the past six months, the relative strength of its shares against the market has been 3.72%. At the current price of €23.2, shares in Evotec SE are trading at 1.67% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Evotec SE PE Ratio?

The Evotec SE PE ratio based on its reported earnings over the past 12 months is 65.86. The shares are currently trading at €23.2.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Evotec SE?

Evotec SE's management team is headed by:

Werner Lanthaler - CEO
Cord Dohrmann - CSO
Iris Loew-Friedrich - VSU
Elaine Sullivan - IND
Enno Spillner - CFO
Michael Shalmi - IND
Craig Johnstone - COO
Wolfgang Plischke - CSU
Iris Loew-Friedrich - VSU
Mario Polywka - IND
Roland Sackers - SUB
Who are the major shareholders of Evotec SE?

Here are the top five shareholders of Evotec SE based on the size of their shareholding:

Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund
Percentage owned: 10.05% (15.2m shares)
T. Rowe Price International (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 10.02% (15.2m shares)
Novo Holdings A/S Venture Capital
Percentage owned: 9.92% (15.0m shares)
Oetker (Roland) Individual Investor
Percentage owned: 9.08% (13.8m shares)
Allianz Global Investors GmbH Investment Advisor
Percentage owned: 5.02% (7.61m shares)
Similar to EVT
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.